How a pharma company grew a vaccine market by changing the conversation in the exam room
CaseSpecialty & High-Specialty PharmaVaccinesOTC

How a pharma company grew a vaccine market by changing the conversation in the exam room

How building persuasive skills in opinion leaders influenced adoption of an adult vaccine

A vaccine with no competitor that still does not sell has an unusual problem. The problem is not the product. It is the people who should be recommending it. That is exactly what a global pharmaceutical company faced when it launched a recombinant adult vaccine in Mexico's private market.

The case

A global pharmaceutical company launched a recombinant adult vaccine in Mexico's private market and worked with Leaderlix on a KOL speaker training program to grow it. The vaccine had no competitor in its category, strong evidence, and a broad profile of eligible patients. Even so, cumulative coverage did not go above five percent.

corporate business professional medical pharmaceutical industry
Foto: Elements Interactive / Pexels

There was no other brand to blame. The problem was not the product but the people who were supposed to recommend it. The challenge was to grow a category that barely existed.

The starting point: a market held back by non-scientific reasons

The company's team identified four barriers that kept physicians from vaccinating during consultations. None of them had to do with the quality of the evidence:

  • The disease was not seen as serious, so there was no sense of urgency.
  • Vaccination was associated with pediatrics and infectious diseases, not with specialties such as cardiology, endocrinology, or nephrology.
  • The pace of the consultation pushed the prevention conversation aside in favor of other topics.
  • Specialists did not see themselves as vaccinators.

The last barrier was the hardest. A physician can know the evidence, believe it, and still not vaccinate, because vaccinating is not part of how they understand their role. Changing that perception was the condition for the market to move.

What we did: working through opinion leaders

The company had opinion leaders who mastered the science and presented it rigorously at congresses, in front of dozens or hundreds of colleagues. But there was a distance between what those leaders communicated and what their colleagues ended up doing in their practice. The evidence got through. The change in practice did not always follow.

Leaderlix came in with a specific hypothesis: an opinion leader who communicates more persuasively generates more vaccination conversations among colleagues. The program did not try to give them more data. It developed their ability to communicate what they already knew in a way that leads to action.

corporate business professional medical pharmaceutical industry
Foto: https://kaboompics.com/ / Pexels

Leaderlix and the company's team built a five-phase initiative together over the course of a year. Each phase had a purpose within a progressive logic, from an individual diagnosis of each participant to measuring the impact on vaccination practice.

Results

The results show what happens when opinion leaders work on their communication with the same discipline they apply to their science. The full case documents the program design, the methodology, the indicators used, and the results at each level of the objectives.

Why it matters to you

If your product has solid evidence but medical practice is not moving, the problem may be how that evidence is communicated between colleagues. See how we run these processes in our communication coaching for medical opinion leaders.

Related service

Coaching for Key Opinion Leaders

See the service →